JNJHealthcare · Drug Manufacturers - General
Johnson & Johnson
DeepValues Research covers Johnson & Johnson (JNJ) with 3 research reports since Feb 15, 2026. The latest Deep Value Intelligence report (Oct 13, 2026) ends with a Neutral stance (3.08/5), with the stock at $264 against a headline intrinsic value of $184. Sector: Healthcare · Drug Manufacturers - General. Neutral since May 13, 2026; 0 stance changes across 2 scored reports since May 13, 2026.
Stance history
Neutral since May 13, 2026; 0 stance changes across 2 scored reports since May 13, 2026.
Research timeline
-
Deep Value Intelligence
Johnson & Johnson (JNJ) Deep Value Intelligence ReportNeutral (3.08/5) on Johnson & Johnson (JNJ), Oct 13, 2026. Price $264 vs intrinsic value $184. Johnson & Johnson remains a high-quality healthcare…
-
Deep Value Intelligence
Johnson & Johnson (JNJ) Deep Value Intelligence ReportNeutral (3.52/5) on Johnson & Johnson (JNJ), May 13, 2026. Price $228. - JNJ looks like a high-quality, low-business-risk company, but not a clear…
-
Deep Value Intelligence
Johnson & Johnson (JNJ) Deep Value Intelligence ReportDeep Value Intelligence report on Johnson & Johnson (JNJ), Feb 15, 2026. Johnson & Johnson remains the "Fortress Balance Sheet" standard of the…
Compare with other Healthcare companies
All Healthcare stocks| Company | Latest stance | Reports |
|---|---|---|
| JNJJohnson & Johnson | Neutral3.08 | 3 |
| ABBVAbbVie | Bullish2.35 | 11 |
| AZNAstraZeneca | Bullish3.33 | 1 |
| LLYEli Lilly and | Neutral3.28 | 2 |
| GRDN | Bearish3.16 | 1 |
| ALLOAllogene Therapeutics | Bearish3.10 | 1 |
| MRNA | Neutral3.01 | 1 |
| CRSPCRISPR Therapeutics | Neutral2.30 | 1 |
| INSMInsmed | Bearish2.52 | 1 |
Charts from the latest report
Open report
